股票简称：华康医疗 股票代码：301235 （修订稿） 保荐机构（主承销商） 武汉华康世纪医疗股份有限公司 Wuhan Huakang Century Medical Co., Ltd. （武汉东湖新技术开发区光谷大道 77 号光谷金融港 B4 栋 8-9 层） 向不特定对象发行可转换公司债券 募集说明书 （无锡市新吴区菱湖大道 200 号中国物联网国际创新园 F12 栋） 二〇二三年九月 武汉华康世纪医疗股份有限公司 募集说明书 发行人声明 本公司及全体董事、监事、高级管理人员承诺募集说明书及其他信息披露资 料不存在任何虚假记载、误导性陈述或重大遗漏，并对其真实性、准确性及完整 性承担相应的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人保证募集说明书中财务 会计资料真实、完整。 中国证监会、交易所对本次发行所作的任何决定或意见，均不表明其对申请 文件及所披露信息的真实性、准确性、完整性作出保证，也不表明其对发行人的 盈利能力、投资价值或者对投资者的收益作出实质性判断或保证。任何与之相反 的声明均属虚假不实陈述。 根据《证券法》的规定，证券依法发行后，发行人经营与收益的变化，由发 行人自行负责。投 ...

股票简称：华康医疗 股票代码：301235 关于武汉华康世纪医疗股份有限公司 申请向不特定对象发行可转换公司债券的 审核问询函 之 回复报告（修订稿） 保荐机构（主承销商） （无锡市新吴区菱湖大道 200 号中国物联网国际创新园 F12 栋） 二〇二三年九月 关于武汉华康世纪医疗股份有限公司申请向不特定对象发行可转换公司债券的审核问询函之回复报告 深圳证券交易所： 贵所于 2023 年 6 月 9 日签发的《关于武汉华康世纪医疗股份有限公司申请 向不特定对象发行可转换公司债券的审核问询函》（审核函〔2023〕020093 号） （以下简称"问询函"）已收悉。根据问询函的要求，武汉华康世纪医疗股份有 限公司（以下简称"华康医疗"、"公司"、"发行人"）会同保荐机构华英证 券有限责任公司（以下简称"华英证券"、"保荐机构"、"保荐人"）、国浩 律师（武汉）事务所（以下简称"发行人律师"）、中汇会计师事务所（特殊普 通合伙）（以下简称"发行人会计师""会计师"）等相关方，本着勤勉尽责、 诚实守信的原则，就审核问询函所提问题逐项认真讨论、核查与落实，并逐项进 行了回复说明。现将相关问题回复如下，请予审核。 说明： 一 ...

国浩律师（武汉）事务所 关于 武汉华康世纪医疗股份有限公司 向不特定对象发行可转换公司债券 之 补充法律意见书（三） 湖北省武汉市洪山区欢乐大道一号宏泰大厦 21 楼 邮编：430077 The 21st floor, Hongtai Building, No. 1 Huanle Avenue, Hongshan District, Wuhan city, Hubei Province, China 电话/Tel: (+86)(027) 87301319 传真/Fax: (+86)(027) 87265677 | 二十、诉讼、仲裁或行政处罚 | 26 | | --- | --- | | 二十一、发行人募集说明书风险评价 | 26 | | 二十二、本次发行的总体结论性意见 | 26 | | 第一轮问询回复更新 第二部分 | 27 | | 一、《审核问询函》问题 1 | 27 | | 第二节 | 签署页 43 | 网址/Website:http://www.grandall.com.cn 二〇二三年九月 | 释 | 义 3 | | --- | --- | | 第一节 | 正文 7 | | 第一部分 相关重大事项更 ...

关于武汉华康世纪医疗股份有限公司 申请向不特定对象发行可转换公司债券的审核问询函 有关财务问题回复的专项说明 中汇会专[2023]9009 号 深圳证券交易所： 根据贵所 2023 年 6 月 9 日出具的《关于武汉华康世纪医疗股份有限公司申 请向不特定对象发行可转换公司债券的审核问询函》(审核函〔2023〕020093 号) (以下简称问询函)的要求，我们作为武汉华康世纪医疗股份有限公司(以下简称 公司或华康医疗公司或发行人) 向不特定对象发行可转换公司债券的申报会计 师，对问询函有关财务问题进行了认真分析，并补充实施了核查程序。现就问询 函有关财务问题回复如下: 问题 1： 报告期内，发行人主营业务收入分别为 75,717.57 万元、85,343.55 万元、 118,009.76 万元和 23,965.52 万元，净利润分别为 5,260.48 万元、8,136.15 万 元、10,248.87 万元和-1,730.95 万元，经营活动产生的现金流量净额分别为 8,464.87 万元、4,459.27 万元、-34,209.79 万元和-20,574.96 万元，净利润与 经营活动产生的现金流量净额变 ...

关于武汉华康世纪医疗股份有限公司申请向不 特定对象发行可转换公司债券的第二轮审核问 询函 审核函〔2023〕020132 号 武汉华康世纪医疗股份有限公司： 根据《证券法》《上市公司证券发行注册管理办法》（以下 简称《注册办法》）、《深圳证券交易所上市公司证券发行上市 审核规则》等有关规定，本所发行上市审核机构对武汉华康世纪 医疗股份有限公司（以下简称发行人或公司）向不特定对象发行 可转换公司债券的申请文件进行了审核，并形成如下审核问询问 题。 1.报告期内，发行人主要通过招投标方式获取医疗净化系统 项目订单。发行人采购的原材料主要包括净化空调、净化装饰材 料、医疗器械及专用设备、电气系统、医用气体系统、信息化系 统等。发行人医疗净化系统集成项目主要通过施工分包方式采购 现场劳务用工。最近三年发行人向前五大施工分包供应商采购金 额分别为 9,323.51 万元、16,791.18 万元和 24,447.57 万元，占 施工分包采购总额的 92.21%、97.65%和 89.76%。 最近三年及一期，发行人销售费用中的广告宣传费分别为 438.98 万元、424.02 万元、1,051.03 万元和 1,035 ...

证券代码:301235 证券简称:华康医疗 武汉华康世纪医疗股份有限公司 投资者关系活动记录表 | --- | --- | --- | |--------------------|---------------------------------------------|-------------------------------------------------------| | | | 编号:2023-003 | | 投资者关系活动类别 | 特定对象调研 □媒体采访 □新闻发布会 现场参观 | | | | 其他(电话会议) | | | | 巨子私募 熊斌;汇添富基金 | 李泽昱;中信建投 李虹达 王在存; | | 参与单位 | 天风证券 钟南;国盛证券 | 夏禹;富荣基金 杨皓童;创金合 | | 名称及人 | 信 皮劲松;民森投资 | 何韦唯;中银国际 经煜甚; | | 员姓名 | 国融证券 赵小小;中欧基金 | 任逸哲;东兴基金 马成骥;国元证券 | | | 马云涛 | | | 时间 | 2023 年 8 月 31 日 | | | 地点 | 电话会议 | | | 上市公司 | | | | 接待人员 ...

Financial Performance - The company's operating revenue for the first half of 2023 was ¥692,998,059.04, representing a 75.15% increase compared to ¥395,664,674.66 in the same period last year[20]. - The net profit attributable to shareholders of the listed company was ¥23,384,155.96, up 40.10% from ¥16,690,785.13 in the previous year[20]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥17,521,016.30, reflecting a 31.38% increase from ¥13,336,548.64 in the same period last year[20]. - The basic earnings per share increased to ¥0.22, a rise of 37.50% compared to ¥0.16 in the previous year[20]. - The total assets at the end of the reporting period were ¥2,561,482,238.89, an increase of 8.08% from ¥2,369,993,275.66 at the end of the previous year[20]. - The net assets attributable to shareholders of the listed company were ¥1,686,207,622.77, up 2.02% from ¥1,652,798,149.51 at the end of the previous year[20]. - The net cash flow from operating activities was -¥251,327,308.73, a decline of 29.95% compared to -¥193,399,831.06 in the same period last year[20]. - The weighted average return on net assets was 1.42%, an increase of 0.22% from 1.20% in the previous year[20]. Business Operations - The medical purification system integration business generated revenue of 583.5014 million yuan, accounting for 84.40% of the main business revenue[45]. - The company secured laboratory orders amounting to 239.838338 million yuan during the reporting period, marking a significant breakthrough in its laboratory business[43]. - The company has a backlog of orders totaling 2.209 billion yuan, with 1.917 billion yuan specifically for purification integration business[42]. - The company aims to enhance its industry influence and build a leading brand image in the medical purification sector through a dual-main and three-auxiliary business layout focusing on integrated solutions[55]. - The company has established 14 marketing operation centers and formed a marketing team of 170 people, creating a nationwide marketing network[58]. Research and Development - R&D expenditure in China reached CNY 308.7 billion in 2022, a 10.4% increase from the previous year, representing 2.55% of GDP[38]. - The company has a strong technical research and development team, capable of customizing medical purification systems for various clinical departments[63]. - The company has made significant investments in technological innovation, developing new technologies and equipment in the medical purification field[68]. - Research and development expenses increased by 101.96% to ¥47,317,298.87, indicating a significant boost in R&D investment during the reporting period[75]. Market Trends - The laboratory construction industry market size increased from CNY 20.2 billion in 2017 to CNY 43.26 billion in 2022, with a compound annual growth rate of 16.4%[37]. - The laboratory construction market is expected to reach CNY 62.3 billion by 2027, with a projected compound annual growth rate of 7.6% from 2022 to 2027[37]. - The aging population and urbanization are driving the continuous growth in demand for medical institutions, with 280 million people aged 60 and above in China by the end of 2022[34]. - The government has increased the health budget for 2023 to CNY 2.42 trillion, an increase of nearly CNY 167 billion from 2022[32]. Financial Management - The company reported a net increase in cash and cash equivalents of ¥117,496,046.88, a rise of 76.52% attributed to increased bank borrowings[75]. - The net cash flow from investing activities improved by 134.53% to ¥189,099,527.26, primarily due to the use of idle raised funds for purchasing financial products[75]. - The company has a total of RMB 50 million available for cash management from idle raised funds, with a rolling usage period of 12 months[99]. - The company has invested RMB 5.01 million in entrusted financial management, with no overdue amounts reported[104]. Corporate Governance - The company plans not to distribute cash dividends or issue bonus shares[4]. - The management has outlined potential risk factors and countermeasures in the report, emphasizing the importance of investor awareness regarding future plans[3]. - The company emphasizes investor relations management through various communication channels, ensuring timely and accurate information disclosure[133]. - The company has implemented a reasonable profit distribution plan to share operational results with shareholders while ensuring sustainable development[133]. Environmental and Social Responsibility - The company actively integrates social responsibility into its development strategy to promote sustainable growth[132]. - The company has not faced any administrative penalties due to environmental issues during the reporting period[128]. - The company has implemented strict management systems and operational procedures to handle environmental concerns effectively[129]. - The company donated 50,000 yuan to the Shanghai Fosun Public Welfare Foundation and 500,000 yuan to the Education Foundation for student assistance during the reporting period[138]. Legal and Compliance - The company reported a total amount involved in litigation of 2,098.08 million yuan related to a construction contract with Zhoushan Ruijin Hospital, which has not yet resulted in a provision for liabilities[148]. - The company is currently involved in a bankruptcy reorganization process for Zhoushan Ruijin Hospital, which has been deemed unable to repay its debts due to severe financial difficulties[148]. - The company has a pending claim for 3,011,647.43 yuan against the People's Liberation Army 988 Hospital for unpaid project fees related to a surgical room purification project[150]. - The company has not engaged in any significant related party transactions during the reporting period[151]. Shareholder Information - The total number of common shareholders at the end of the reporting period was 8,470[178]. - The largest shareholder, Tan Pingtao, holds 44.23% of the shares, totaling 46,708,990 shares[178]. - The company reported a total share count of 105,600,000, with 76.29% (80,558,504 shares) being subject to restrictions prior to the recent changes[172]. - The company plans to lift restrictions on certain shares, with specific dates for release ranging from January 28, 2023, to July 28, 2025[175].

武汉华康世纪医疗股份有限公司 关于召开 2023 年第三次临时股东大会的通知 证券代码： 301235 证券简称：华康医疗 公告编号：2023-082 本公司及董事会全体成员保证信息披露的内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 武汉华康世纪医疗股份有限公司（以下简称"公司"）于2023年8月29日召开了 第二届董事会第九次会议，决定于2023年9月14日（星期四）下午14:30召开2023年 第三次临时股东大会。为了进一步保护投资者的合法权益，方便公司股东行使表决 权，本次股东大会将采用现场投票与网络投票相结合的方式，根据有关规定，现将 股东大会的相关事项通知如下： 一、会议召开基本情况 1、股东大会届次：2023年第三次临时股东大会 2、股东大会召集人：公司董事会 3、会议召开的合法、合规性：公司第二届董事会第九次会议审议通过了《关于召 开2023年第三次临时股东大会的议案》，本次股东大会的召开符合有关法律、行政法 规、部门规章、规范性文件和《公司章程》的规定。 4、会议召开日期、时间： 现场会议召开时间：2023年9月14日（星期四）下午14:30。 网络投票时间：2023年9月1 ...

证券代码：301235 证券简称：华康医疗 公告编号：2023-076 武汉华康世纪医疗股份有限公司 第二届董事会第九次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 一、董事会会议召开情况 武汉华康世纪医疗股份有限公司（以下简称"华康医疗"或"公司"）第二届董 事会第九次会议于 2023 年 8 月 29 日（星期二）在公司会议室召开。会议通知于 2023 年 8 月 18 日以电话及邮件方式送达全体董事。本次会议应到董事 7 人，实到董事 7 人。会议由董事长谭平涛先生主持。 本次会议的召开符合《中华人民共和国公司法》、《武汉华康世纪医疗股份有限 公司章程》（以下简称"《公司章程》"）以及有关法律、法规的规定。 （一）审议通过《关于<2023年半年度报告>及其摘要的议案》 公司董事会编制的公司2023年半年度报告及其摘要的程序符合法律、行政法规和 中国证券监督管理委员会的相关规定，报告内容真实、准确、完整，不存在虚假记载、 误导性陈述或重大遗漏。 公司出具了《2023年半年度非经营性资金占用及其他关联资金往来情况汇总表》， 公司独立董事对公司 ...